article Open AccessTop 1% cited
ESMO Clinical Practice Guideline for the diagnosis, staging and treatment of patients with metastatic breast cancer
Annals of Oncology · 2021 · Vol. 32(12) · pp. 1475–1495
Alessandra Gennari✉(Università degli Studi del Piemonte Orientale “Amedeo Avogadro”)Fabrice André(Institut Gustave Roussy)Carlos H. Barrios(Grupo Hospitalar Conceição)Javier Cortés(Universidad Europea)Evandro de Azambuja(Université Libre de Bruxelles)A. DeMichele(Hospital of the University of Pennsylvania)Rebecca Dent(National Cancer Centre Singapore)Deborah Fenlon(Swansea University)Joseph Gligorov(Assistance Publique – Hôpitaux de Paris)Sara A. Hurvitz(University of California, Los Angeles)Seock‐Ah Im(Seoul National University Hospital)David Krug(University Hospital Schleswig-Holstein)Wolfgang G. Kunz(LMU Klinikum)Sherene Loi(Peter MacCallum Cancer Centre)Frédérique Penault‐Llorca(Université Clermont Auvergne)Jens Ricke(Ludwig-Maximilians-Universität München)Mark E. Robson(Memorial Sloan Kettering Cancer Center)Hope S. Rugo(University of California, San Francisco)Cristina Saura(Vall d'Hebron Institute of Oncology)Peter Schmid(Cancer Research UK)Christian F. Singer(Medical University of Vienna)Tanja Španič(Alma Mater Europaea)Sara M. Tolaney(Dana-Farber Cancer Institute)Nicholas C. Turner(Royal Marsden Hospital)Giuseppe Curigliano(University of Milan)Sibylle Loibl(German Breast group)Shani Paluch–Shimon(Hebrew University of Jerusalem)Nadia Harbeck(Ludwig-Maximilians-Universität München)
Advanced Breast Cancer TherapiesHER2/EGFR in Cancer ResearchBreast Cancer Treatment StudiesMedicineGuidelineMetastatic breast cancerBreast cancerClinical PracticeOncologyCancerInternal medicineFamily medicinePathology
MeSH terms
Breast NeoplasmsFemaleHumansMedical Oncology
Citations
1,287
FWCI
121.08
field-weighted impact
References
96
Percentile
100%
vs. same field & year
Citations per year
References
Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phase 3 randomised controlled trial
The Lancet Oncology · 2016 · 1,795 citations
3rd ESO–ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 3)
Annals of Oncology · 2016 · 2,058 citations
Global surveillance of trends in cancer survival 2000–14 (CONCORD-3): analysis of individual records for 37 513 025 patients diagnosed with one of 18 cancers from 322 population-based registries in 71 countries
The Lancet · 2018 · 6,007 citations
5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5)
Annals of Oncology · 2020 · 1,319 citations
Citation Network
How this paper connects to the literature. Drag to explore, click any node to open that paper.